Key facts
- This page summarizes Mark Patrick Guerin's Form 4 filing for Onconova Therapeutics, Inc. (TRAW).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Feb 2024, 17:38.
Mark Patrick Guerin - 07 Feb 2024 Form 4 Insider Report for Onconova Therapeutics, Inc. (TRAW)
- Reporting relationship
- CFO AND COO
- Issuer ticker
- TRAW
- Reported as of
- 07 Feb 2024
- Net transaction value
- -$1,637
- SEC form
- 4
- Accepted by SEC
- 09 Feb 2024, 17:38:14 UTC
- Prior SEC filing
- 04 Aug 2023
- Next SEC filing
- 15 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Guerin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Patrick Guerin filed Form 4 for Onconova Therapeutics, Inc. (TRAW) on 09 Feb 2024.
Change
- Previous filing in this sequence was filed on 04 Aug 2023.
- Current net transaction value: -$1,637.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,900
- Change %
- +27%
- Price
- Shares after
- 32,344
- Date
- 07 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ONTX
transaction
Common Stock
Tax liability
- Transaction value
- $1,637
- Shares
- -2,443
- Change %
- -7.6%
- Price
- $0.6700
- Shares after
- 29,901
- Date
- 07 Feb 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ONTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -6,900
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 6,900
- Date
- 07 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,900
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
On February 7, 2022 the reporting person was granted 20,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.